SCHEMBL6786599

SCHEMBL6786599

CCOC(=O)c1cc(N(C)C)ccc1NC(=O)/C=C(/C)c1ccc(Cl)c(Cl)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.47
MAPT P10636 4/20 0.41
NPSR1 Q6W5P4 1/20 0.41
ALDH1A1 P00352 5/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
RAB9A P51151 3/20 0.41
KMT2A Q03164 3/20 0.41
NPC1 O15118 2/20 0.41
MAPK1 P28482 2/20 0.41
GAA P10253 1/20 0.40
TSHR P16473 1/20 0.40
RECQL P46063 1/20 0.40
TERT O14746 3/20 0.39
POLB P06746 1/20 0.39
CETP P11597 2/20 0.39
L3MBTL1 Q9Y468 1/20 0.38
CYP1A2 P05177 2/20 0.38
KDM4E B2RXH2 1/20 0.38
CYP2C19 P33261 1/20 0.38
MEN1 O00255 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6781172 0.86 TERT (0.51) MAPTALDH1A1SMN1; SMN2RAB9AKMT2A
SCHEMBL6784141 0.85 TERT (0.58) LMNAMAPTNPSR1ALDH1A1SMN1; SMN2
SCHEMBL6791903 0.79 TERT (0.43) LMNAMAPTALDH1A1RAB9AKMT2A
SCHEMBL6785534 0.79 TERT (0.59) LMNAMAPTALDH1A1SMN1; SMN2KMT2A
SCHEMBL6785976 0.78 TERT (0.44) MAPTALDH1A1RAB9AKMT2ANPC1
SCHEMBL6791528 0.77 SMN1; SMN2 (0.55) MAPTNPSR1ALDH1A1SMN1; SMN2RAB9A
SCHEMBL6787326 0.76 TERT (0.42) LMNAMAPTALDH1A1SMN1; SMN2RAB9A
SCHEMBL6787305 0.76 TERT (0.53) LMNAALDH1A1SMN1; SMN2GAATSHR
SCHEMBL6787120 0.75 TERT (0.55) LMNAMAPTALDH1A1SMN1; SMN2KMT2A
SCHEMBL6786749 0.74 TERT (0.52) LMNAALDH1A1SMN1; SMN2KMT2AGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6727250-B2 ADMINISTERING COMPOUNDS SUCH AS TRANS-3-(NAPHTH-2-YL)-BUT-2-ENOIC ACID-N-(2-CARBOXY-PHENYL)-AMIDE OR LIKE FOR THERAPY OF CONDITIONS ASSOCIATED WITH INCREASED TELOMERASE ACTIVITY, E.G. TUMOUR DISEASES BOEHRINGER INGELHEIM PHARMA KG (DE) 2004-04-27 US disclosed
US-20020099089-A1 Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and preparation BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2002-07-25 US disclosed
US-6362210-B1 ANTITUMOR, ANTICANCER AGENT BOEHRINGER INGELHEIM PHARMA KG (DE) 2002-03-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020099089-A1 Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and preparation TERT, NAT1, POT1 LMNA 169/4885MAPT 1221/4885NPSR1 4663/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.